Cargando…
Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice
Cholesterol 24-hydroxylase (CH24H) is a brain-specific enzyme that converts cholesterol into 24S-hydroxycholesterol, the primary mechanism of cholesterol catabolism in the brain. The therapeutic potential of CH24H activation has been extensively investigated, whereas the effects of CH24H inhibition...
Autores principales: | Nishi, Toshiya, Kondo, Shinichi, Miyamoto, Maki, Watanabe, Sayuri, Hasegawa, Shigeo, Kondo, Shigeru, Yano, Jason, Watanabe, Etsurou, Ishi, Tsuyoshi, Yoshikawa, Masato, Ando, Haruhi Kamisaki, Farnaby, William, Fujimoto, Shinji, Sunahara, Eiji, Ohori, Momoko, During, Matthew J., Kuroita, Takanobu, Koike, Tatsuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553946/ https://www.ncbi.nlm.nih.gov/pubmed/33051477 http://dx.doi.org/10.1038/s41598-020-74036-6 |
Ejemplares similares
-
Anticonvulsive properties of soticlestat, a novel cholesterol 24‐hydroxylase inhibitor
por: Nishi, Toshiya, et al.
Publicado: (2022) -
Soticlestat, a novel cholesterol 24‐hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice
por: Hawkins, Nicole A., et al.
Publicado: (2021) -
Preclinical characterization of [(18)F]T-008, a novel PET imaging radioligand for cholesterol 24-hydroxylase
por: Koike, Tatsuki, et al.
Publicado: (2021) -
Population pharmacokinetics, enzyme occupancy, and 24S‐hydroxycholesterol modeling of soticlestat, a novel cholesterol 24‐hydroxylase inhibitor, in healthy adults
por: Yin, Wei, et al.
Publicado: (2023) -
Clinical Characterization of [(18)F]T-008, a Cholesterol 24-Hydroxylase PET Ligand: Dosimetry, Kinetic Modeling, Variability, and Soticlestat Occupancy
por: Constantinescu, Cristian C., et al.
Publicado: (2023)